Patents Assigned to Genentech
  • COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH A CD79b ANTIBODY-DRUG CONJUGATE
    Publication number: 20180344848
    Abstract: The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with a CD79b antibody-drug conjugate for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody and a CD79b antibody-drug conjugate.
    Type: Application
    Filed: August 10, 2018
    Publication date: December 6, 2018
    Applicants: Hoffmann-La Roche Inc., Genentech, Inc.
    Inventors: Christian Klein, Sabine Lang, Pablo Umana, Andrew Polson
  • METHODS FOR DIAGNOSING AND TREATING INFLAMMATORY BOWEL DISEASE
    Publication number: 20180346576
    Abstract: Biomarkers predictive of responsiveness to integrin beta7 antagonists, including anti-beta7 integrin subunit antibodies, and methods of using such biomarkers are provided. In addition, methods of treating gastrointestinal inflammatory disorders such as inflammatory bowel diseases including ulcerative colitis and Crohn's disease are provided. Also provided are methods of using such predictive biomarkers for the treatment of inflammatory bowel diseases including ulcerative colitis and Crohn's disease.
    Type: Application
    Filed: December 18, 2017
    Publication date: December 6, 2018
    Applicant: Genentech, Inc.
    Inventors: Mary Keir, Gaik Wei Tew
  • SUBSTITUTED BENZAMIDES USEFUL AS SODIUM CHANNEL BLOCKERS
    Publication number: 20180346441
    Abstract: The invention provides compounds having the general formula (I): and pharmaceutically acceptable salts thereof, wherein the variables RA, RAA, n, ring A, X2, L, m, R1, R2, R3, R4, R5, and RN have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Application
    Filed: November 22, 2016
    Publication date: December 6, 2018
    Applicants: GENENTECH, INC., XENON PHARMACEUTICALS INC.
    Inventors: Chien-an CHEN, Sultan CHOWDHURY, Shannon Marie DECKER, Christoph Martin DEHNHARDT, Ivan William HEMEON, Steven MCKERRALL, Brian SAFINA, Tao SHENG, Dan SUTHERLIN
  • N-SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF
    Publication number: 20180346416
    Abstract: The invention provides methods for treating pain using compounds having the general formula: and pharmaceutically acceptable salts thereof, wherein the variables RA, subscript n, ring A, X2, L, subscript m, X1, ring D, R1, and RN have the meaning as described herein.
    Type: Application
    Filed: August 7, 2018
    Publication date: December 6, 2018
    Applicants: GENENTECH, INC., XENON PHARMACEUTICALS INC.
    Inventors: Christoph Martin DEHNHARDT, Sultan CHOWDHURY, Thilo FOCKEN, Michael Edward GRIMWOOD, Ivan William HEMEON, Brian Salvatore SAFINA, Daniel P. SUTHERLIN
  • METHODS OF TREATING CANCER USING ANTI-OX40 ANTIBODIES
    Publication number: 20180346586
    Abstract: The invention provides methods of treating or delaying progression of cancer in an individual comprising administering to the individual an anti-human OX40 agonist antibody. In some embodiments, the antibody is administered in a dose selected from about 0.2 mg, about 0.8 mg, about 3.2 mg, about 12 mg, about 40 mg, about 80 mg, about 130 mg, about 160 mg, about 300 mg, about 320 mg, about 400 mg, about 600 mg, and about 1200 mg.
    Type: Application
    Filed: May 11, 2018
    Publication date: December 6, 2018
    Applicant: Genentech, Inc.
    Inventors: Ina P. RHEE, Jeong KIM, Mahrukh HUSENI, Eric STEFANICH, Sid SUKUMARAN, Chi-Chung LI
  • ANTI-ANGIOGENESIS THERAPY FOR THE TREATMENT OF OVARIAN CANCER
    Publication number: 20180344847
    Abstract: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents for the treatment of ovarian cancer.
    Type: Application
    Filed: August 9, 2018
    Publication date: December 6, 2018
    Applicant: Genentech, Inc.
    Inventors: Jakob Dupont, Cornelia Irl, Amreen Husain, Mika A. Sovak, Jing Yi, Hoa Nguyen
  • METHODS FOR THE TREATMENT OF EPILEPSY
    Publication number: 20180340028
    Abstract: The invention provides methods for the treatment of seizures and epilepsy using FGF21 receptor activators.
    Type: Application
    Filed: March 20, 2018
    Publication date: November 29, 2018
    Applicant: Genentech, Inc.
    Inventor: Sharmila Rajan
  • POLYMORPHS AND SOLID FORMS OF (S)-2-((2-((S)-4-(DIFLUOROMETHYL)-2-OXOOXAZOLIDIN-3-YL)-5,6-DIHYDROBENZO[F]IMIDAZO[1,2-D][1,4]OXAZEPIN-9-YL)AMINO)PROPANAMIDE, AND METHODS OF PRODUCTION
    Publication number: 20180339997
    Abstract: The present invention relates to crystalline polymorph forms of (S)-2-((2-((S)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide (GDC-0077), having the structure, Formula I: or stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, and processes of preparing the polymorph forms.
    Type: Application
    Filed: April 26, 2018
    Publication date: November 29, 2018
    Applicant: Genentech, Inc.
    Inventors: Paroma Chakravarty, Chong Han, Sean M. Kelly, Karthik Nagapudi, Scott Savage
  • THERAPEUTIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF USE THEREOF
    Publication number: 20180333416
    Abstract: Compounds and salts thereof that are useful as JAK kinse inhibitors are described herein. Also provided are pharmaceutical compositions that include such a JAK inhibitor and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.
    Type: Application
    Filed: May 21, 2018
    Publication date: November 22, 2018
    Applicant: Genentech, Inc.
    Inventors: Mark ZAK, F. Anthony ROMERO, Yun-Xing CHENG
  • THERAPEUTIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF USE THEREOF
    Publication number: 20180334465
    Abstract: Compounds and salts thereof that are useful as JAK kinase inhibitors are described herein. Also provided are pharmaceutical compositions that include such a JAK inhibitor and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.
    Type: Application
    Filed: May 21, 2018
    Publication date: November 22, 2018
    Applicant: Genentech, Inc.
    Inventors: Mark ZAK, F. Anthony ROMERO, Yun-Xing CHENG, Wei LI
  • Cell culture compositions with antioxidants and methods for polypeptide production
    Patent number: 10131873
    Abstract: Cell culture media comprising antioxidants are provided herein as are methods of using the media for cell culturing and polypeptide production from cells. Compositions comprising polypeptides, such as therapeutic polypeptides, produced by the methods herein are also provided.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: November 20, 2018
    Assignee: GENENTECH, INC.
    Inventors: Natarajan Vijayasankaran, Steven J. Meier, Sharat Varma, Yi Yang
  • Tricyclic DLK inhibitors and uses thereof
    Patent number: 10131675
    Abstract: The invention relates to compounds of formula (I) and salts thereof: wherein ring A and R1-R2 have any of the values defined in the specification. The compounds and salts are useful for treating DLK mediated disorders. The invention also provides pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, as well as methods of using said compounds, salts, or compositions as DLK inhibitors and for treating neurodegeneration diseases and disorders.
    Type: Grant
    Filed: September 8, 2017
    Date of Patent: November 20, 2018
    Assignee: Genentech, Inc.
    Inventors: Anthony Estrada, Snahel Patel, Terry Kellar, Malcolm Huestis, Daniel Shore, Michael Siu
  • Aryl sultam derivatives as RORc modulators
    Patent number: 10131644
    Abstract: Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, n, p, q, r, X1, X2, X3, X4, Y, Z, A, R1, R2, R3, R4, R5 R6, R7, R8, R9, R10, R11, R12 and R13 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis, muscular sclerosis and psoriasis.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: November 20, 2018
    Assignee: Genentech, Inc.
    Inventors: Monique Bodil van Niel, Benjamin Fauber, Emanuela Gancia, Simon Gaines, Alberto Gobbi, Christopher Hurley, Tammy Ladduwahetty, Olivier Rene, David Vesey, Stuart Ward, Paul Winship
  • PYRROLOBENZODIAZEPINE ANTIBODY DRUG CONJUGATES AND METHODS OF USE
    Publication number: 20180326062
    Abstract: The invention provides antibody-drug conjugates comprising an antibody conjugated to a pyrrolobenzodiazepine drug moiety via a disulfide linker, pyrrolobenzodiazepine linker-drug intermediates, and methods of using the antibody-drug conjugates.
    Type: Application
    Filed: July 16, 2018
    Publication date: November 15, 2018
    Applicant: Genentech, Inc.
    Inventors: Peter Dragovich, Thomas Pillow, Jack Sadowsky, Mark X. Sliwkowski, BinQing Wei
  • HUMANIZED ANTIBODY
    Publication number: 20180327485
    Abstract: The present invention is related to chimeric and humanized antibody and to methods and compositions for the therapeutic and diagnostic use in the treatment of amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease.
    Type: Application
    Filed: December 4, 2017
    Publication date: November 15, 2018
    Applicants: AC Immune S.A., Genentech, Inc.
    Inventors: Andrea Pfeifer, Maria Pihlgren, Andreas Muhs, Ryan Watts
  • METHODS AND COMPOSITIONS FOR DETECTING AND TREATING DRUG RESISTANT AKT MUTANT
    Publication number: 20180327860
    Abstract: Methods for identifying or diagnosing AKT inhibitor resistant cancers and methods an compositions for treating.
    Type: Application
    Filed: May 8, 2018
    Publication date: November 15, 2018
    Applicant: GENENTECH, INC.
    Inventor: Kui Lin
  • TRIAZOLOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20180327402
    Abstract: Provided are triazolopyridine compounds that are inhibitors of JAK kinase, such as JAK1, compositions containing these compounds and methods for treating diseases mediated by a JAK kinase. In particular, provided are compounds of formula (I), stereoisomers, tautomers, solvates, prodrugs or pharmaceutically acceptable salts thereof, where R1a, R1b, R1c, R2, R3, R4 and R5 are defined herein, pharmaceutical compositions comprising the compound and a pharmaceutically acceptable carrier, adjuvant or vehicle, methods of using the compound or composition in therapy, for example, for treating a disease or condition mediated by a JAK kinase in a patient.
    Type: Application
    Filed: May 9, 2018
    Publication date: November 15, 2018
    Applicant: Genentech, Inc.
    Inventors: Simon Charles Goodacre, Nicholas Charles Ray, Mark Edward Zak, Yun-Xing Cheng, Wei Li
  • ANTI-CD79b ANTIBODIES AND METHODS OF USE
    Publication number: 20180327492
    Abstract: The invention provides anti-CD79b antibodies and methods of using the same.
    Type: Application
    Filed: April 19, 2018
    Publication date: November 15, 2018
    Applicant: Genentech, Inc.
    Inventors: Liping L. Sun, Yvonne Man-Yee Chen, Mark S. Dennis, Allen J. Ebens, JR., Andrew Polson
  • FIXED DOSING OF HER ANTIBODIES
    Publication number: 20180327510
    Abstract: The present invention concerns fixed dosing of HER antibodies, such as Pertuzumab.
    Type: Application
    Filed: March 2, 2018
    Publication date: November 15, 2018
    Applicant: Genentech, Inc.
    Inventors: DAVID E. ALLISON, RENE BRUNO, JIAN-FENG LU, CHEE M. NG
  • TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE
    Publication number: 20180327420
    Abstract: Described herein are tricyclic compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such PI3K modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon PI3K dysregulation.
    Type: Application
    Filed: July 25, 2018
    Publication date: November 15, 2018
    Applicant: Genentech, Inc.
    Inventors: Marie-Gabrielle Braun, Keira Garland, Emily Hanan, Hans Purkey, Steven T. Staben, Robert Andrew Heald, Jamie Knight, Calum Macleod, Aijun Lu, Guosheng Wu, Siew Kuen Yeap